Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
July 25, 2017 6:30 AM EDTCompany provides update on long-term growth strategy
SPINRAZA approved in Europe, Japan, and Canada for spinal muscular atrophy
Company acquires Phase-3 ready stroke asset from Remedy Pharmaceuticals
Company completes exclusive license agreement with Bristol-Myers Squibb for Phase-2 anti-tau antibody with potential in Alzheimers disease and progressive supranuclear palsy
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2017 financial results, including:
Total revenues of $3.1 billion, a 6% increase versus the prior year and a 15%... More